Valerio Therapeutics S.A.
ALVIO.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.12 | -0.01 | -0.02 | 0.02 |
| FCF Yield | -36.41% | -51.17% | -41.84% | -37.58% |
| EV / EBITDA | -251.15 | -8.03 | -2.72 | -3.80 |
| Quality | ||||
| ROIC | -6.42% | -82.65% | -48.28% | -33.60% |
| Gross Margin | -1,482.54% | -168.78% | -83.15% | 82.56% |
| Cash Conversion Ratio | 17.32 | 0.43 | 0.62 | 1.09 |
| Growth | ||||
| Revenue 3-Year CAGR | -9.10% | -16.01% | -29.22% | -32.22% |
| Free Cash Flow Growth | 37.20% | 14.07% | 28.13% | -3.75% |
| Safety | ||||
| Net Debt / EBITDA | -153.19 | -4.14 | -0.98 | -0.30 |
| Interest Coverage | -7.21 | -23.35 | -182.08 | 361.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 52.33 |
| Cash Conversion Cycle | 3,189.10 | -11.63 | 1,735.08 | -608.05 |